Day: March 2, 2021

KAPALUA RESORT, Hawaii, March 01, 2021 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) reported a net loss of $2.6 million, or $(0.14) per share, for the year ended December 31, 2020. This compares to a net loss of $10.4 million, or $(0.54) per share, for 2019. The Company reported revenues of $7.5 million and $10.0 million for 2020 and 2019, respectively.For the fourth quarter of 2020, the Company recognized a net loss of $0.7 million, or $(0.04) per share. In 2019, the Company recognized a net loss of $9.1 million or $(0.47) per share for the fourth quarter. Operating revenues totaled $2.1 million and $2.5 million during the fourth quarters of 2020 and 2019, respectively.In 2020, the disruption of the COVID-19 pandemic on global and national economies, as well as restrictions on travel and public gatherings,...

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphatemia in Canada.   IBSRELA was approved by Health Canada on April 15, 2020 and is now covered by most private insurance companies in Canada.IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal...

MONTRÉAL, 01 mars 2021 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd’hui la mise en marché au Canada de IBSRELA (tenapanor), thérapie de pointe pour le traitement du syndrome du côlon irritable avec constipation (SCI-C) chez les adultes. Knight détient le droit exclusif de commercialisation de IBSRELA selon les modalités d’une entente de licence conclue avec Ardelyx, Inc. (NASDAQ : ARDX) en mars 2018, une entente de licence qui octroie également à Knight l’exclusivité des droits de commercialisation de tenapanor pour l’hyperphosphatémie au Canada. IBSRELA a été approuvé par Santé Canada en date du 15 avril 2020 et est désormais couvert par la majorité des compagnies d’assurance privées au Canada.IBSRELA est une petite molécule à...